Mesoblast (NASDAQ:MESO) Rating Reiterated by Cantor Fitzgerald

Mesoblast (NASDAQ:MESO)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports.

Separately, StockNews.com cut Mesoblast from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $13.67.

Mesoblast Price Performance

MESO opened at $7.01 on Thursday. The business has a 50 day simple moving average of $7.06 and a 200-day simple moving average of $4.11. The stock has a market capitalization of $800.39 million, a P/E ratio of -6.26 and a beta of 3.46. Mesoblast has a 12 month low of $1.61 and a 12 month high of $10.24.

Hedge Funds Weigh In On Mesoblast

An institutional investor recently bought a new position in Mesoblast stock. Chase Investment Counsel Corp acquired a new stake in Mesoblast Limited (NASDAQ:MESO) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 59,600 shares of the company’s stock, valued at approximately $298,000. Chase Investment Counsel Corp owned approximately 0.05% of Mesoblast at the end of the most recent reporting period. Institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.